28 Aug 2016 Jahr - FDA announced required class-wide changes to
drug labeling to help inform health care providers
and patients of the serious risks associated with
the combined use of certain opioid medications
and a class of central nervous system depressant
drugs called benzodiazepines. Among the
changes, the FDA is requiring boxed warnings
and Medication Guides.
Zugefügt zum Band der Zeit:
Opioids and the FDA
Datum:
